More earnings analysis: https://betafinch.com Groups: RETAIL (https://betafinch.com/groups/RETAIL), INCOME (https://betafinch.com/groups/INCOME) ────────── ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown of the companies moving the market. Today we're digging into Colgate-Palmolive's second quarter 2026 results. Before we get into it — quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. JORDAN: And there was a lot to dig into here, Alex. This was a "good news, but with an asterisk" kind of quarter. ALEX: Exactly. Let's start with the headline numbers. Colgate delivered organic sales growth in four of five geographic divisions and three of four product categories. Gross margin expanded 100 basis points to a level that's up 90 basis points versus last quarter. Free cash flow was up 18%, and they returned $1.4 billion to shareholders. CFO Stan Sutula even raised the full-year gross margin guidance to roughly flat for the year — up from a prior expectation of a decline. JORDAN: That raise is notable because it's not just a fluke — management said it's coming from real execution: revenue growth management, productivity, favorable mix, plus a modest one-time tariff refund benefit that they don't expect to repeat. ALEX: Right, and CEO Noel Wallace was pretty upfront that this was a global story — emerging markets were the star again, up mid-single digits, led by India, Brazil, Mexico, and China. JORDAN: India in particular jumped out to me — double-digit growth in the quarter. And Latin America was strong too: Brazil up high single digits, Mexico mid-single digits, with a nice balance between pricing and volume. They're also lapping last year's Colgate Total reformulation issue, and those shares are coming back nicely, especially in Brazil. ALEX: But — and here's the asterisk — the U.S. business was the soft spot. Wallace didn't sugarcoat it, saying the North America team was "disappointed" with the quarter. JORDAN: Yeah, a few things stacked up there. May saw a sharp category slowdown tied to spiking gas prices hitting consumer confidence. There was heightened competitive activity, and retailers pulled back inventory — so shipments came in below actual consumption, roughly consumption flat versus shipments down 3%. ALEX: There was a great exchange with an analyst about that exact gap between what tracking data shows and what Colgate actually reports. Wallace admitted part of it is inventory destocking, but he was candid that they also lost a bit of share in untracked channels — so it's not purely a data mismatch, there's real competitive pressure in there too. JORDAN: What I liked was the specificity of the fix. It's not just "we'll try harder" — they identified select price gaps versus competitors in certain retailers and categories, and they're stepping up advertising in the back half, which is a real financial commitment given ad spend is already sitting near 20-year highs as a percentage of sales. ALEX: One analyst actually pushed on that — is 14% of sales the right ad spend level, or is that masking soft ROI given organic growth is only running 2 to 3%? Wallace's answer was basically: their data and digital measurement capabilities have improved a lot, ROI on digital and social specifically looks strong, and ultimately it's about long-term brand health, not just quarterly efficiency. JORDAN: Let's talk pets, because Hill's continues to be a genuine bright spot. Ex-private label, organic growth of 4%, well ahead of a category that's basically flat. The therapeutic and premium science-led segments are doing the heavy lifting there. ALEX: And there's a longer-term storyline brewing with the Prime brand and this new "Fresh" launch — single-protein, vet-recommended, science-first position This episode includes AI-generated content.
